At McGill’s D2R initiative, our researchers are pioneering the next generation of RNA-based technologies. Our growing portfolio of inventions spans a wide spectrum of RNA science, each designed to advance therapeutic development, diagnostics, and cutting-edge biotechnology.
All featured inventions have active patent filings, and we are actively seeking industry partners interested in collaboration—whether through sponsored research, co-development opportunities, or licensing agreements.
This portfolio represents only a portion of the RNA innovation happening across D2R. If you are exploring RNA solutions or scouting emerging technologies, we invite you to connect with our team to discover additional inventions and partnership possibilities.
Discover our portfolio of inventions:
| PRINCIPAL INVESTIGATOR | INVENTION TITLE |
|---|---|
| Carl Ernst |
Antisense Oligonucleotide for the Treatment of SETBP1 Gain-Of-Function Syndromes |
| Hanadi Sleiman | Introducing Chemical Functionality in Nucleic Acids and Sequence Controlled Polymers |
| Hanadi Sleiman | Engineered Dendritic Conjugates Platform |
| Hanadi Sleiman | Nuclease-Resistant Small-Molecule/DNA Hydrogel |
|
Hanadi Sleiman and Maureen McKeague |
DNA-encoded Libraries of Highly Functionalized Aptamer-like Ligands |
| Masad Damha | CRISPR-Cas12a crRNA with Non-Nucleotide Structures |
| Masad Damha | CRISPR-Cas12a RNA Analogues for Gene Editing |
| Masad Damha | Tuning CRISPR/Cas9 Activity with Chemically Modified Nucleotide Substitutions |
| Masad Damha | Anti-CRISPR Nucleic Acid Inhibitors of CRISPR-Cas Effector Enzymes |
| Nathan Luedtke | Novel Compositions of RNA |
Want to discuss or know more about our D2R Inventions?
Get in touch with sarah.butcher [at] mcgill.ca (Sarah Butcher, D2R Technology Transfer Manager).
Want to know more about industry opportunities?
Contact janet.prince [at] mcgill.ca (Janet Prince, D2R Associate Director, Business Development and Innovation).
